Pharmaceutical giant GlaxoSmithKline (GSK), which recently pleaded guilty to the largest drug industry scandal in recorded history (http://www.naturalnews.com), has partnered with an India-based pharmaceutical company to develop a six-in-one, single-dose vaccine jab that will deliver vaccine material for polio, diphtheria, tetanus, whooping cough (pertussis), hepatitis B, and Haemophilus influenzae type B specifically to the world’s poorest people living in developing countries.
According to reports, GSK will add the contents of its injectable polio shot to a pentavalent vaccine already being manufactured by Biological E Ltd. that contains the other five vaccines. Together, as part of a 50-50 joint venture, the two companies will manufacture the hexavalent vaccine, which will rival similar combination vaccines for polio currently being developed and administered by rival drug companies in India such as Serum Institute of India Ltd. and Sanofi Pasteur.
The purpose of this monstrous six-in-one vaccine, of course, is not necessarily to protect children against polio and these various other diseases — as we reported back in April, a study published in the Indian Journal of Medical Ethics (IJME) found that cases of polio-related paralysis have skyrocketed as a result of widespread polio vaccine campaigns throughout India, which means the populations of India are not benefiting from existing polio vaccines as the vaccine industry claims they are (http://www.naturalnews.com/035588_polio_vaccine_India_paralysis.html). To the contrary, GSK is merely trying to boost its own vaccine market share in India for the purpose of increasing profits.
As explicitly stated in a recent Bloomberg report, GSK’s current efforts with Biological E Ltd. will help the company “gain market share” by giving it a much stronger foothold in one of the fastest-growing developing nations in the world. No mention is made of how the vaccine will supposedly help children in light of the polio vaccine-induced paralysis epidemic — GSK’s bottom line is the sole focus of the endeavor, and the mainstream media admits this.
Similar multi-vaccine jabs linked to serious side effects, death
Back in 2004, GSK introduced a similar six-in-one mega vaccine for children in Australia. That particular vaccine, known as Infanrix hexa, has been implicated in causing a high number of serious, adverse events and death in infants and children, as brought to light by the Belgian watchdog group Initiative Citoyenne back in 2011. According to the data, Infanrix hexa was found to have induced sudden infant death syndrome (SIDS) in at least 36 children between October 23, 2009, and October 22, 2011, almost all of which occurred within three days of receiving the injection. (http://vran.org/in-the-news/can-infanrix-hexa-kill-babies/)
Back in 2008, a similar pentavalent vaccine manufactured by drug giant Sanofi Pasteur was pulled from doctors’ offices throughout the Chicago area after it was discovered that administering a high number of vaccines all at once as a single injection could be fatal to children. Like the new hexavalent vaccine currently being developed by GSK, Sanofi’s pentavalent vaccine, known as Pentacel, contains vaccines for diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae type B. (http://newsblogs.chicagotribune.com)
Sources for this article include: